Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Avalo Therapeutics (AVTX) over the last 12 years, with Q3 2025 value amounting to $3.2 million.

  • Avalo Therapeutics' Share-based Compensation rose 7067.1% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 22269.07%. This contributed to the annual value of $5.9 million for FY2024, which is 6830.6% up from last year.
  • As of Q3 2025, Avalo Therapeutics' Share-based Compensation stood at $3.2 million, which was up 7067.1% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' Share-based Compensation peaked at $5.3 million during Q1 2022, and registered a low of $471000.0 during Q2 2024.
  • Moreover, its 5-year median value for Share-based Compensation was $1.4 million (2021), whereas its average is $1.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 8390.44% in 2023, then surged by 47707.01% in 2025.
  • Avalo Therapeutics' Share-based Compensation (Quarter) stood at $1.9 million in 2021, then tumbled by 55.44% to $843000.0 in 2022, then dropped by 7.95% to $776000.0 in 2023, then surged by 274.23% to $2.9 million in 2024, then rose by 8.61% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $2.7 million for Q2 2025, and $3.2 million during Q1 2025.